NM09 is an anti-TNF antibody fragment in development for inflammatory bowel disease (IBD), a chronic inflammatory condition of the digestive tract encompassing ulcerative colitis and Crohn’s disease. Anti-TNF therapies have been shown to reduce hospitalizations, decrease the need for surgical interventions, and improve patients’ quality of life. Numab’s highly stable antibody fragment NM09 demonstrates best-in-class potency and is licensed to Mage Biologics for the development and commercialization of innovative formulations.

ND059 is being developed in collaboration with Boehringer Ingelheim and targets geographic atrophy, a progressive and irreversible retinal disease affecting patients with age-related macular degeneration and lacking any approved therapies. The collaboration combines Boehringer Ingelheim’s leading expertise in the research and development of life-changing breakthrough therapies with Numab’s multispecific antibody platform.

ND047 is a collaborative project with Boehringer Ingelheim with the goal to develop a T-cell engager for the treatment of gastrointestinal cancer based on Numab’s multi-specific antibody platform.

NM26-2198 is a bispecific antibody that targets IL-4Rα (type I and type II receptors) and IL-31 for the treatment of atopic dermatitis (AD). NM26-2198 is designed to prevent IL-4/IL-13- and IL-31-induced keratinocyte immunopathology, immune cell activation, skin-barrier impairment, and pruritus, all of which are hallmarks of atopic dermatitis pathophysiology. Targeting the IL-4/IL-13 pathway is well established for the treatment of AD and other inflammatory diseases. We believe that adding IL-31-mediated blockade of neuroinflammation to the suppression of Th2-driven inflammation by IL-4/IL-13 inhibition could enable a faster onset of action and improved efficacy compared with the current standard of care in AD, while allowing convenient subcutaneous administration.